MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells

The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cance...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageEnglish
Published 25.11.2014
Online AccessGet full text

Cover

Abstract The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).
AbstractList The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).
BookMark eNqNjLsKwkAQAK_Qwtc_bKnFwaEEkloiWqSRNFaynBuzsNkLuYuQvzeFH2A1zcyszUKD0so8qtvdHp2DBjuWCVhfo6cIHUVS304dik3BUs-pJWEUSANq5MRBYV-V9WFOIHxwYFTwqJ4G8CQSt2bZoETa_bgxcCnr89WOscdEmuLzPa9muDwvsswVpz-ULwEWO_Q
ContentType Patent
CorporateAuthor Georgia Tech Research Corporation
CorporateAuthor_xml – name: Georgia Tech Research Corporation
DBID EFH
DatabaseName USPTO Issued Patents
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EFH
  name: USPTO Issued Patents
  url: http://www.uspto.gov/patft/index.html
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
ExternalDocumentID 08895509
GroupedDBID EFH
ID FETCH-uspatents_grants_088955093
IEDL.DBID EFH
IngestDate Sun Mar 05 22:31:48 EST 2023
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-uspatents_grants_088955093
OpenAccessLink https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8895509
ParticipantIDs uspatents_grants_08895509
PatentNumber 8895509
PublicationCentury 2000
PublicationDate 20141125
PublicationDateYYYYMMDD 2014-11-25
PublicationDate_xml – month: 11
  year: 2014
  text: 20141125
  day: 25
PublicationDecade 2010
PublicationYear 2014
References (WO 2009/036332) 20090300
(2341145) 20110700
(WO 2010/048123) 20100400
(WO 2008/138578) 20081100
Lyon et al. (2011/0091562) 20110400
Clarke et al. (2011/0021607) 20110100
(WO 2009/097136) 20090800
Frisch (5516631) 19960500
(WO 2009/143379) 20091100
Khew-Goodall et al. (2010/0088775) 20100400
Bader et al. (2009/0163435) 20090600
(WO 2008/036765) 20080300
(WO 2011/099007) 20110800
(WO 2010/056737) 20100500
(WO 2010/005741) 20100100
(WO 2011/088226) 20110700
(WO 2011/106709) 20110900
(WO 2009/100430) 20090800
References_xml – year: 20090800
  ident: WO 2009/100430
– year: 20110100
  ident: 2011/0021607
– year: 20110900
  ident: WO 2011/106709
– year: 20110700
  ident: WO 2011/088226
– year: 19960500
  ident: 5516631
– year: 20080300
  ident: WO 2008/036765
– year: 20100500
  ident: WO 2010/056737
– year: 20090800
  ident: WO 2009/097136
– year: 20081100
  ident: WO 2008/138578
– year: 20110700
  ident: 2341145
– year: 20100100
  ident: WO 2010/005741
– year: 20090300
  ident: WO 2009/036332
– year: 20100400
  ident: 2010/0088775
– year: 20110400
  ident: 2011/0091562
– year: 20091100
  ident: WO 2009/143379
– year: 20090600
  ident: 2009/0163435
– year: 20100400
  ident: WO 2010/048123
– year: 20110800
  ident: WO 2011/099007
Score 2.8966928
Snippet The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian...
SourceID uspatents
SourceType Open Access Repository
Title MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
URI https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8895509
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfVxLSwMxEB7aIqgnRcXWBzl40EO07Dtn6bIKK0Uq1FPJJqke9sVuqvjvndmV4kWvCRmGySTfzDDfAFwJpRyjjMv70s1UOzxDnOdSYXRi1soPQyI4p09B8uI9Lv3lAJItF6bAZ8Rr1KW93bS1rbrmSvze-4vn_fBnmhFY0vSBzzKvpJ7r9V0UCQy2xRCG6GEUFsXJPuyiCAzZStv-Ao34AHbm3eohDEx5BK_pwzN5C-trCgyTYTRrywri_6j3r0Lm3Fbc1MSSyNEtmCUc6Vqq2HU6W9zgEVZ9YHIrS6bothpGdff2GFg8W9wnfKvH6q2h_pbV9Edf9wRGmOebU2CujDzliigUWniRMVHgi8BXUmPK4SqdjWH8p5jJP3tnsIco7xGBzvHPYWSbjblAJLXZZWemb4rafz0
linkProvider USPTO
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfVxLT8MwDLbGQDxOIECMZw4c4BCY-s4ZWnVApwoNaZyqNMng0JfaDsS_x2nRxAWuiRJZtpPPtvwZ4JIJYSihTNqXbsbSoCniPOUCoxO1ELbraoJzNHXCF-thbs8HEK64MDk-I1qhLM3NsqnasmuuxO-9Nzzthz_rGYGFnj7wWWQll7Fc3Hoew2CbrcE6epShn6gfhDuwhZdg0Fa0zS_YCHZhI-5W92Cgin14jSbP2l9IX1UgmA6jYhuSawaQeP_KeUbbkqpK8yQydAzSaiTpmqrIVeTPrvEIKT8wveUFEdpeNdGV9-YASODP7kK6kiN5q3WHSzL-kdg8hCFm-uoIiMk9S5jMc5lklqeU59jMsQWXmHSYQqYjGP15zfE_exewGd8HydNk-ngC2wj5lmbTGfYpDNt6qc4QVtv0vNPYN-M9gi0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=MIR-200+family+induces+mesenchymal-to-epithelial+transition+%28MET%29+in+ovarian+cancer+cells&rft.number=8895509&rft.date=2014-11-25&rft.externalDBID=n%2Fa&rft.externalDocID=08895509